Development of next-generation antibody therapeutics by improving effector functions
نویسندگان
چکیده
منابع مشابه
Next Generation Antibody Therapeutics Using Bispecific Antibody Technology.
Nearly fifty monoclonal antibodies have been approved to date, and the market for monoclonal antibodies is expected to continue to grow. Since global competition in the field of antibody therapeutics is intense, we need to establish novel antibody engineering technologies to provide true benefit for patients, with differentiated product values. Bispecific antibodies are among the next generatio...
متن کاملEngineered protein scaffolds as next-generation antibody therapeutics.
Antibodies have been the paradigm of binding proteins with desired specificities for more than one century and during the past decade their recombinant or humanized versions have entered clinical application with remarkable success. Meanwhile, a new generation of receptor proteins was born, which is derived from small and robust non-immunoglobulin "scaffolds" that can be equipped with prescribe...
متن کاملNext-Generation Therapeutics for IBD
Various novel drugs have recently been evaluated in clinical trials showing promising effects in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-α4β7) and etrolizumab (anti-rhuMAb β7), and the Janus kinase (JAK) inhibitor tofa...
متن کاملNext generation therapeutics for Alzheimer's disease
To date, no truly effective therapy has been developed for Alzheimer's disease or mild cognitive impairment. In searching for new approaches that may succeed where previous ones have failed, it may be instructive to consider the successful therapeutic developments for other chronic illnesses such as cancer and human immunodeficiency virus.
متن کاملPolyclonals: A Third Generation of Antibody Therapeutics
for over a century. Traditional immunoglobulin therapy has the advantage of reflecting the diversity of the natural immune response, but has limited clinical applications. During the past 10 years, many monoclonal antibodies have been successfully introduced to the market. The monoclonal antibody approach has the advantage of specificity, but often lacks efficacy in the treatment of diseases ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Delivery System
سال: 2011
ISSN: 1881-2732,0913-5006
DOI: 10.2745/dds.26.611